排序方式: 共有16条查询结果,搜索用时 343 毫秒
11.
Open D-ring galanthamine analogues were prepared using ring-opening reactions of the quaternarized urethane or oxazolidine functions and were evaluated for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibition potency. 相似文献
12.
13.
Activity of novel Cdc25 inhibitors and preliminary evaluation of their potentiation of chemotherapeutic drugs in human breast cancer cells 总被引:1,自引:0,他引:1
Dual-specific phosphatases Cdc25 play a critical role in the cell cycle regulation by activating kinases of Cdk/cyclin complexes. Three Cdc25 isoforms (A, B and C) have been identified in mammalians. Cdc25A and B display oncogenic properties and are over-expressed in different tumors. Cdc25 phosphatases are therefore attractive targets for therapeutic strategies. Novel maleic anhydride derivatives bearing a fatty acid chain of variable size have been synthesized and tested for their Cdc25 inhibitory potential using an in vitro assay. We report biological activity of ineffective, moderate, and efficient inhibitors on breast cancer cells (MCF7) and its counterpart resistant to vincristine (Vcr-R). The most potent compounds induced Cdk2 inhibition and accumulation in G0/G1 phase of the cell cycle. Moreover, apoptosis was triggered within 48-h treatment, without oxidative burst and modulation of the Bax to Bcl-2 ratio. When used as pre-treatments, these derivatives were also able to potentiate adriamycin and cisplatin toxicity in both cell lines. Thus, maleic anhydride derivatives may mediate apoptosis through a cell cycle blockage via inhibition of Cdc25. This class of inhibitors may present potential interest in therapeutic strategies against cancer. 相似文献
14.
Allosteric potentiation of acetylcholine nicotinic receptors is considered to be one of the most promising approaches for
the treatment of Alzheimer’s disease. However, the exact localization of the allosteric binding site and the potentiation
mechanism at the molecular level are presently unknown. We have performed the “blind docking” of three known allosteric modulators
(galanthamine, codeine and eserine) with the Acetylcholine Binding Protein and models of human α7, α3β4 and α4β2 nicotinic
receptors, created by homology modeling. Three putative binding sites were identified in the channel pore, each one showing
different affinities for the ligands. One of these sites is localized opposite to the agonist binding site and is probably
implicated in the potentiation process. On the basis of these results, a possible mechanism for nicotinic acetylcholine receptor
(nAChRs) activation is proposed. The present findings may represent an important advance for understanding the allosteric
modulation mechanism of nAChRs.
Electronic supplementary material Supplementary material is available for this article at 相似文献
15.
Denyse Moriceau-Hay Jeannine Doerr-Schott Maurice P. Dubois 《Cell and tissue research》1982,225(1):57-64
Summary By use of the immunofluorescence technique TSH-, LH- and ACTH-cells were localized in the hypophysis of tadpoles of Xenopus laevis. The first signs of the activity of these cells were observed in early stages of the development, i.e., stage 39 for ACTH, and stage 42 for TSH and LH. 相似文献
16.
E Sibille E Bana W Chaouni M Diederich D Bagrel P Chaimbault 《Analytical biochemistry》2012,430(1):83-91
The cell division cycle 25 phosphatases (CDC25s) are key regulators of the physiological cell cycle progression. Their overexpression has been reported in a significant number of cancers, and their inhibition appears to be an interesting strategy for treatments. We propose here a rapid screening test allowing the detection of reversible and irreversible CDC25A and -C inhibitors. The test is based on the incubation of the candidate molecules with the human CDC25 proteins followed by an ultrafiltration step. The retentate is then directly analyzed by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOFMS) to detect reversible inhibitors or submitted to peptide mass fingerprint (PMF) analysis to reveal irreversible inhibitors covalently bound to the protein active site. After its validation, the protocol is applied to the detection of a novel candidate inhibitor of CDC25s named SV37. The screening procedure, as well as the preliminary biological results, demonstrates that this compound behaves as a reversible inhibitor. 相似文献